Persistent diabetic macular edema (P-DME), a challenging manifestation of diabetic retinopathy unresponsive to conventional anti-VEGF therapy, lacks standardized management strategies; however, newer agents may offer improved outcomes. To address this gap, a real-world study evaluated the anatomical and functional outcomes of intravitreal brolucizumab 6 mg/0.05 ml in 13 patients, mean age of 64.4 years, with chronic P-DME. The study found that eyes treated with intravitreal brolucizumab showed a significant improvement in visual acuity (VA), with median VA increasing from 0.40 logMAR (20/50) to 0.35 logMAR (20/44) after a mean follow-up of 13 weeks.
Central retinal thickness also reduced markedly from 517 µm to 237 µm. One case of intraocular inflammation occurred, which resolved with topical steroids, and subsequent brolucizumab administration did not result in recurrence. These…
